Education
About Us
Working with TipRanks
Follow Us
Cns Pharmaceuticals, Inc. (CNSP)
NASDAQ:CNSP
CNSP Stock Chart & Stats
$9.20
<$0.01(4.42%)
At close: 4:00 PM EST
$9.20
<$0.01(4.42%)
Day’s Range― - ―
52-Week Range$4.93 - $114.00
Previous CloseN/A
Volume19.26M
Average Volume (3M)11.73K
Market Cap
$4.04M
Enterprise Value-$4.80M
Total Cash (Recent Filing)$9.86M
Total Debt (Recent Filing)$30.79K
Price to Earnings (P/E)―
Beta2.32
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.76
Shares Outstanding620,290
10 Day Avg. Volume19,959
30 Day Avg. Volume11,726
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.71
Price to Sales (P/S)0.00
P/FCF Ratio-1.34
Enterprise Value/Market Cap-1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.24K
Enterprise Value/Ebitda0.37
Forecast
1Y Price Target
$20.00Price Target Upside117.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-31.41
Revenue Forecast (FY)$23.20M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsTPI-287 demonstrated an overall response rate of 60% in a Phase 1 trial for rGBM, with a 96% disease control rate, indicating promising efficacy.
Regulatory ProspectsThe totality of data could support a formal discussion with the FDA around a potential filing or accelerated approval pathway for Berubicin without another trial.
Strategic DevelopmentCNS Pharmaceuticals is upgrading shares to Buy due to the pivot to its oncology asset TPI-287, which is in development for recurrent glioblastoma (rGBM).
Bears Say
Market PerformanceCNS Pharmaceuticals shares are at an all-time low due to the Berubicin trial missing its primary endpoint in March.
Trial ResultsBerubicin’s trial did not meet the primary OS endpoint, causing uncertainty about its effectiveness.
CNS Pharmaceuticals News
CNSP FAQ
What was Cns Pharmaceuticals, Inc.’s price range in the past 12 months?
Cns Pharmaceuticals, Inc. lowest stock price was $4.93 and its highest was $114.00 in the past 12 months.
What is Cns Pharmaceuticals, Inc.’s market cap?
Cns Pharmaceuticals, Inc.’s market cap is $4.04M.
When is Cns Pharmaceuticals, Inc.’s upcoming earnings report date?
Cns Pharmaceuticals, Inc.’s upcoming earnings report date is May 18, 2026 which is in 145 days.
How were Cns Pharmaceuticals, Inc.’s earnings last quarter?
Cns Pharmaceuticals, Inc. released its earnings results on Nov 12, 2025. The company reported -$5.76 earnings per share for the quarter, beating the consensus estimate of -$6.63 by $0.87.
Is Cns Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Cns Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Cns Pharmaceuticals, Inc. pay dividends?
Cns Pharmaceuticals, Inc. does not currently pay dividends.
What is Cns Pharmaceuticals, Inc.’s EPS estimate?
Cns Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cns Pharmaceuticals, Inc. have?
Cns Pharmaceuticals, Inc. has 620,290 shares outstanding.
What happened to Cns Pharmaceuticals, Inc.’s price movement after its last earnings report?
Cns Pharmaceuticals, Inc. reported an EPS of -$5.76 in its last earnings report, beating expectations of -$6.63. Following the earnings report the stock price went down -2.08%.
Which hedge fund is a major shareholder of Cns Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in CNSP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cns Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
CNSP Stock 12 Month Forecast
Average Price Target
$20.00
▲(117.39% Upside)
Technical Analysis
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Oragenics
―
InMed Pharmaceuticals
―
GRI Bio
―
Ownership Overview
60.17%
Insiders
0.24% Mutual Funds
2.27% Other Institutional Investors
37.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---